ClinicalTrials.gg

TargetBeta

TENT4A

terminal nucleotidyltransferase 4A · also POLK, TRF4, LAK-1, TRF4-1 · Non-canonical poly(A) polymerases

1 program in company-led studies act on TENT4A, from 1 company: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
GSK-3965193GlaxoSmithKlinephase 210 runningTENT4Bthe company's pipeline

Also acted on by the same programs

Conditions their studies are in

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.